Pharmeasy

PharmEasy CEO Siddharth Shah steps down amid string of co-founder exits; Rahul Guha takes over

Rahul Guha, who currently serves as CEO of subsidiary Thyrocare and President of Operations at API, will take over from Siddharth Shah, the last remaining co-founder of the company, who will now assume the role of Vice Chairman.

PharmEasy co-founders Dharmil Sheth, Dhaval Shah and Hardik Dedhia to start new consumer venture together

The outgoing founders will continue to hold shares in the company and remain on the board but have expressed willingness to reduce their involvement in active day-to-day executive responsibilities.

PharmEasy co-founders Dharmil Sheth, Dhaval Shah, Harsh Parekh and Hardik Dedhia to leave troubled startup

The founder group cumulatively holds under 2 percent in API Holdings. Each of the five co-founders held between 0.20 percent to 0.30 percent stake in the company, data showed.

Swiggy Instamart looks to strengthen pharmacy play 10-minute medicine deliveries

To be sure, Swiggy was already delivering basic over the counter medicines such as pain relief sprays and others through Instamart, the company’s quick commerce arm.

PharmEasy raises $216 million at a 90% lower valuation from peak

The online pharmacy was last valued at $5.6 billion in 2021, followed by nearly 90 percent decrease in its valuation amidst debt repayment related challenges.

Tata 1mg credits pricing for market share gains, says didn't go crazy like rivals during good times

Discount-centric strategies, favoured by some of the Tata 1mg’s rivals, are unsustainable in the long term, co-founder Gaurav Agarwal said

Naspers, Temasek get CCI nod to buy stakes in PharmEasy

API Holdings, through its subsidiaries, is in the business of providing healthcare services through online e-commerce marketplace PharmEasy.

PharmEasy CEO hopes to return to market with an IPO if robust performance sustains

The company is awaiting Competition Commission of India (CCI) approval for the rights issue.

Byju’s, Pharmeasy among biggest underperformers in Prosus' India portfolio in H1

According to the firm’s half yearly financials, while Byju’s reported a negative internal rate of return (IRR) of 24 percent, Pharmaeasy gave Prosus 41 percent negative returns in H1 FY24.

Diagnostic players shun discounts, opt for the premium route

Most new-age diagnostic players moved away from heavy discounts and are now raising prices. With this, the difference in pricing between incumbents and established players is narrowing and moving towards a level-playing field

Pharmeasy to seek funding from Manipal only in case of shortfall in rights issue

The Manipal Group's family office had made a binding offer to invest up to Rs 1,300 crore in the online pharmacy